<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120584</url>
  </required_header>
  <id_info>
    <org_study_id>DO609175A</org_study_id>
    <nct_id>NCT04120584</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Safety and Efficacy of Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction</brief_title>
  <official_title>Clinical Evaluation of Safety and Efficacy of Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and efficacy of radiofrequency treatment for&#xD;
      dry eye disease due to meibomian gland dysfunction&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Standardized patient Evaluation of Eye Dryness (SPEED)</measure>
    <time_frame>1month, 3 months, 6 months</time_frame>
    <description>Mean change from baseline to prior to second, third treatments as well as four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) in Standardized Patient Evaluation of Eye Dryness (SPEED)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>1 Month, 3 months, 6 months</time_frame>
    <description>Mean change from baseline to prior to second, third treatments as well as four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) in Ocular Surface Disease Index (OSDI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in NEI grading measurements</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Improvement measurements using ocular surface fluorescent staining. NEI grading scheme grading for ocular surface staining score will be used in this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Meibomian Gland Score (MGS), as assessed by a masked rater</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Changes from baseline to prior to second, third treatments as well as four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) in in Meibomian Gland Score (MGS), as assessed by a masked rater, and Tear Break-Up Time (TBUT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tear Break-Up Time</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Changes from baseline to prior to second, third treatments as well as four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) assessed by Tear Break-up time (TBUT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of improvement</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Subject assessment of improvement based on 0 - 4-point Likert scale at four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) follow up visits. Improvement assessment will be performed independently by the subject himself on the following 0-4 points Likert scale questionnaire (Global Aesthetic Improvement Scale):&#xD;
4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of satisfaction</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Subject assessment of satisfaction will be filled-out by subjects only using 5-points Likert scale at four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) follow up visits:&#xD;
+2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>The number, severity and type of any adverse event recorded throughout the study and post treatment (immediate and delayed response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>2 weeks, 4 weeks and 6 weeks</time_frame>
    <description>Discomfort assessment during the treatment using NSR scale. At each treatment the subject will be asked to fill assessments for the pain/discomfort during the procedure. The subject will be asked to rate the severity from 0 to 10, with 0 equaling no symptoms and 10 equaling the worst possible symptoms. A number is obtained by measuring up to the point the subject has indicated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Improvement of Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Forma Eye treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Forma Eye Applicator</intervention_name>
    <description>Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.&#xD;
The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment.</description>
    <arm_group_label>Forma Eye treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult females and males between the ages of 18 -75, seeking treatments for Dry Eye&#xD;
             Disease Due to Meibomian Gland Dysfunction&#xD;
&#xD;
          2. Tear breakup time (TBUT) ≤10 s;&#xD;
&#xD;
          3. Evidence of meibomian gland (MG) obstruction, based on total MGS of ≤12 in lower&#xD;
             eyelids for each eye as assessed by a clinician not involved in the study procedure&#xD;
&#xD;
          4. Subjective symptom score (using the Standard Patient Evaluation of Eye Dryness [SPEED]&#xD;
             questionnaire) ≥10;&#xD;
&#xD;
          5. At least one meibomian gland opening with a visible plugging over the eyelid margin&#xD;
&#xD;
          6. No ocular pathology requiring treatment other than eye lubricant and conventional&#xD;
             eyelid hygiene within the last month and during the study&#xD;
&#xD;
          7. The subjects should understand the information provided about the investigative nature&#xD;
             of the treatment, possible benefits, and side effects, and sign the Informed Consent&#xD;
             Form&#xD;
&#xD;
          8. The subjects should be willing to comply with the study procedure and schedule,&#xD;
             including follow up visits.&#xD;
&#xD;
          9. Agreement/ability to abstain from dry eye/MGD medications or any device treatments for&#xD;
             the time between the treatment visit and the final study visit. Ocular lubricants are&#xD;
             allowed if no changes are made during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of co-existing ocular conditions potentially posing an increased risk of&#xD;
             procedure-related injury, (e.g., active ocular infection or inflammation in either&#xD;
             eye)&#xD;
&#xD;
          2. History of ocular trauma or surgery including intraocular, oculoplastic, corneal or&#xD;
             refractive surgery within 1 year&#xD;
&#xD;
          3. Ocular surface abnormality potentially compromising corneal integrity in either eye;&#xD;
             eyelid abnormalities affecting lid function in either eye&#xD;
&#xD;
          4. Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome,&#xD;
             vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis,&#xD;
             leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren's syndrome)&#xD;
&#xD;
          5. Unwillingness to abstain from systemic medications known to cause dryness for the&#xD;
             study duration.&#xD;
&#xD;
          6. Individuals who have either changed the dosing of systemic or non-dry eye/MGD&#xD;
             ophthalmic medication within the past 30 days prior to screening&#xD;
&#xD;
          7. Internal defibrillator, a pacemaker or any other implanted electrical device anywhere&#xD;
             in the body&#xD;
&#xD;
          8. Permanent metal implant in the treatment area&#xD;
&#xD;
          9. Any surgery in the treatment area in the last 3 months&#xD;
&#xD;
         10. Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or pre-malignant moles&#xD;
&#xD;
         11. Pregnancy and nursing or females of childbearing potential and not utilizing adequate&#xD;
             birth control measures&#xD;
&#xD;
         12. Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use&#xD;
             of immunosuppressive medications&#xD;
&#xD;
         13. Patients with a history of diseases stimulated by heat, such as recurrent Herpes&#xD;
             Simplex in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
         14. Poorly controlled endocrine disorders, such as diabetes, thyroid dysfunction,&#xD;
             polycystic ovary, and hormonal virilization&#xD;
&#xD;
         15. Any active condition in the treatment area, such as but not limited to open sores,&#xD;
             psoriasis, eczema, vitiligo, herpes, and rash.&#xD;
&#xD;
         16. History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin&#xD;
&#xD;
         17. Severe concurrent conditions, such as cardiac disorders, sensory disturbances.&#xD;
&#xD;
         18. Use of Isotretinoin (Accutane®) within 6 months prior to treatment.&#xD;
&#xD;
         19. Participation in another study within 30 days prior to screening.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>4316 James Casey St Building F Suite 201, Austin, TX 78745, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandy Zhang-Nunes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oculofacial Plastic Surgery Director USC Roski Eye Institue USC Keck School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Abdulla</last_name>
    <phone>949.305.0106</phone>
    <email>maureen.abdulla@inmodemd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Shusterman</last_name>
    <phone>855.411.2639</phone>
    <email>marias@inmodemd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sean Paul</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Paul, MD</last_name>
      <phone>512-642-5050</phone>
      <email>kathryn@aopsurgery.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

